FBR's COVID-19 Resources

We're committed to improving health through education

Nearly every medicine, medical device, surgical procedure and therapy we have today has depended on animal testing and research. Animal research is one of the first steps in medical discovery.

“There are diseases in which you vaccinate someone, they get infected with what you are trying to protect them with, and you actually enhance the infection. You can get a good feel for that in animal models,” the director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, said during a White House briefing on March 26.

Contrary to the claims of animal rights groups, animal models have been and will continue to be crucial to medical development and public health. 

The FBR team rounded up articles in the news in recent weeks on potential treatments and potential vaccines for the new coronavirus, as well as other COVID-19 developments, and the animal models used to develop them. In addition, Genetic Engineering & Biotechnology News put together a list (found here) of potential COVID-19 treatments in development.

Basic Research

We would like to say a word about the role of research animals in basic research to understand how COVID-19 infects humans and animals. A basic research study in macaque monkeys revealed that monkeys who recovered from COVID-19 developed some immunity to the SARS-COV-2 virus and did not get reinfected with the virus. Further basic research studies will be conducted to confirm these results. Several other teams of researchers are studying how the SARS-COV-2 virus jumped from animals to humans by using data from studies of other coronaviruses like SARS and MERS in bats, civets, pangolins, and camels. Here are a few good articles on basic research to understand the zoonotic transmission of COVID-19 from animals to humans:

2022
JULY

July 27: ‘Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves,’ BMJ

July 26: ‘Development of transgenic models susceptible and resistant to SARS-CoV-2 infection in FVB background mice,’ PLOS One

July 26: ‘The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2,’ Science

July 23: ‘SARS-ANI: a global open access dataset of reported SARS-CoV-2 events in animals,’ Scientific Data

July 21: ‘Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern,’ PLOS Pathogens

July 19: ‘Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines,’ Science

July 12: ‘ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies,’ Science

July 12: ‘Broadly neutralizing antibodies target the coronavirus fusion peptide,’ Science

July 7: ‘SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice,’ Science Translational Medicine

July 5: ‘Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species,’ PLOS Pathogens

July 3: ‘Preclinical immunogenicity and efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 vaccine,’ Vaccines

July 1: ‘Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model,’ iScience

JUNE

June 30: ‘Identification of potent SARS-CoV-2 macrodomain inhibitors,’ News Medical

June 30: ‘Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations,’ PLOS Pathogens

June 23: ‘Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters,’ Science

June 21: ‘Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis,’ PLOS Pathogens

June 20: ‘SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters,’ Nature Communications

June 17: ‘Special focus on SARS-CoV-2 and other zoonotic respiratory coronaviruses in animal models,’ Journal of Veterinary Pathology

June 14: ‘Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,’ Science

June 9: ‘Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein,’ Critical Care

June 2: ‘Nonhuman primate models for evaluation of SARS-CoV-2 vaccines,’ Expert Review of Vaccines

June 1: ‘SARS CoV-2 (delta variant) infection kinetics and immunopathogenesis in domestic cats,’ Viruses

MAY

May 31: ‘Adverse effects following anti–COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes,’ PLOS Biology

May 24: ‘A single dose of the deactivated rabies-virus vectored COVID-19 vaccine, CORAVAX, is highly efficacious and alleviates lung inflammation in the hamster model,’ Viruses

May 18: ‘Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination,’ Nature

May 16: ‘Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2,’ Nature

May 12: ‘The role of NSP6 in the biogenesis of the SARS-CoV-2 replication organelle,’ Nature

May 10: ‘Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants,’ bioRxiv

May 10: ‘Exposure route influences disease severity in the COVID-19 cynomolgus macaque model,’ Viruses

May 5: ‘Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates,’ PLOS Biology

APRIL

April 29: ‘Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models,’ Cell Discovery

April 28: ‘Inflammasome activation in infected macrophages drives COVID-19 pathology,’ Nature

April 26: ‘Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19,’ News Medical

April 26: ‘An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo,’ Science Translational Medicine

April 20: ‘Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation,’ PLOS Pathogens

April 14: ‘Multi-site proficiency testing for validation and standardization of assays to detect specific pathogen-free viruses, coronaviruses, and other agents in nonhuman primates,’ Journal of Medical Primatology

April 11: ‘Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques,’ PLOS Pathogens

April 8: ‘Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2,’ Nature Medicine

April 6: ‘FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation,’ Nature

MARCH

March 31: ‘Defining the risk of SARS-CoV-2 variants on immune protection,’ Nature

March 28: ‘A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic,’ Nature

March 25: ‘Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission,’ PLOS Pathogens

March 24: ‘Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2,’ PLOS Pathogens

March 24: ‘Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529,’ Science

March 21: ‘Transcriptome analysis of lungs in a mouse model of severe COVID-19,’ Frontiers

March 21: ‘Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19,’ Nature

March 18: ‘Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains,’ bioRxiv

March 17: ‘Maintenance of mitochondrial integrity in midbrain dopaminergic neurons governed by a conserved developmental transcription factor,’ Nature Communications

March 10: ‘The immunology and immunopathology of COVID-19,’ Science

March 8: ‘KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19,’ Science

March 7: ‘MRNA-based vaccine candidate COReNAPCIN® induces robust humoral and cellular immunity in mice and non-human primates,’ bioRxiv

March 7: ‘Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns,’ PLOS Pathogens

March 5: ‘Fatal neurodissemination and SARS-CoV-2 tropism in K18-hACE2 mice Is only partially dependent on hACE2 expression,’ Viruses

March 3: ‘Assessing the potential of IFNa subtypes in suppressing SARS-CoV-2,’ News Medical

March 1: ‘Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine,’ Proceedings of the National Academy of Sciences of the United States of America

March 1: ‘Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models,’ Science Translational Medicine

FEBRUARY

Feb. 28: ‘Multiscale PHATE identifies multimodal signatures of COVID-19,’ Nature Biotechnology

Feb. 25: ‘Highly divergent white-tailed deer SARS-CoV-2 with potential deer-to-human transmission,’ bioRxiv

Feb. 23: ‘Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients,’ PLOS One

Feb. 22: ‘Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection,’ Proceedings of the National Academy of Sciences of the United States of America

Feb. 22: ‘A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques,’ Science Translational Medicine

Feb. 17: ‘More autopsy studies are needed to understand the pathogenesis of severe COVID-19,’ Nature Medicine

Feb. 17: ‘Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung,’ PLOS Pathogens

Feb. 16: ‘Bat coronaviruses related to SARS-CoV-2 and infectious for human cells,’ Nature

Feb. 16: ‘Why does the Omicron sub-variant spread faster than the original?’ Nature

Feb. 15: ‘Germinal centre-driven maturation of B cell response to mRNA vaccination,’ Nature

Feb. 10: ‘The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters,’ PLOS Pathogens

Feb. 10: ‘Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination,’ Science

Feb. 10: ‘Activation of immune system may cause pathophysiological changes in the myocardium of SARS-CoV-2 infected monkey model,’ Cells

Feb. 9: ‘Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil,’ Nature Medicine

Feb. 8: ‘The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate,’ PLOS One

Feb. 8: ‘A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection,’ Science Translational Medicine

Feb. 7: ‘Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2,’ Nature

Feb. 8: ‘Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody,’ Science

Feb. 2: ‘CRISPR-based assay reveals SARS-CoV-2 RNA dynamic changes and redistribution patterns in non-human primate model,’ Emerging Microbes & Infections

Feb. 2: ‘What the omicron wave is revealing about human immunity,’ Nature

Feb. 1: ‘SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo,’ Nature

Feb. 1: ‘Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity,’ Nature

Feb. 1: ‘Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant,’ Nature

JANUARY

Jan. 31: ‘Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron,’ Nature

Jan. 29: ‘Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques,’ Emerging Microbes & Infections

Jan. 28: ‘Human genetic and immunological determinants of critical COVID-19 pneumonia,’ Nature

Jan. 28: ‘Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants,’ Nature

Jan. 25: ‘Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement,’ Science

Jan. 25: ‘The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in human,’ Science Translational Medicine

Jan. 21: ‘Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron,’ Nature

Jan. 19: ‘The cGAS-STING pathway drives type I IFN immunopathology in COVID-19,’ Nature

Jan. 19: ‘An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies,’ Nature Medicine

Jan. 19: ‘Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B,’ Science

Jan. 17: ‘The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste,’ Nature Genetics

Jan. 14: ‘Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant,’ Nature Medicine

Jan. 13: ‘Advances and gaps in SARS-CoV-2 infection models,’ PLOS Pathogens

Jan. 12: ‘Immunogenicity of a recombinant VSV-Vectored SARS-CoV vaccine induced robust immunity in rhesus monkeys after single-dose immunization,’ Virologica Sinica

Jan. 10: ‘Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain,’ bioRxiv

Jan. 7: ‘A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection,’ Science Advances

Jan. 6: ‘Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry,’ Science

2021
DECEMBER

BREAKING NEWS: Dec. 30: ‘P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants,’ News Medical

Dec. 30: ‘Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection,’ Science Translational Medicine

Dec. 29: ‘Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: An institutional comparative review,’ Docwirenews.com

Dec. 27: ‘Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human primate models and confers a large plaque phenotype,’ BioRxiv

Dec. 24: ‘An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19,’ Science

Dec. 23: ‘An integrated platform for serological detection and vaccination of COVID-19,’ Frontiers in Immunology

Dec. 23: ‘Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift,’ Nature

Dec. 23: ‘Evolution of enhanced innate immune evasion by SARS-CoV-2,’ Nature

Dec. 23: ‘Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization,’ Nature

Dec. 22: ‘Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta,’ Nature

Dec. 22: ‘Local and systemic responses to SARS-CoV-2 infection in children and adults,’ Nature

Dec. 21: ‘Activity of galidesivir in a hamster model of SARS-CoV-2,’ Viruses

Dec. 20: ‘Single-cell immunology of SARS-CoV-2 infection,’ Nature Biotechnology

Dec. 20: ‘Booster shots improve CD8+ T cell response to SARS-CoV-2 in animal model,’ News-medical.net

Dec. 20: ‘Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination mouse models,’ The Lancet

Dec. 16: ‘A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2,’ PLOS Pathogens

Dec. 16: ‘A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates,’ Science Translational Medicine

Dec. 10: ‘Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA,’ Science Immunology

Dec. 8: ‘The emergence, genomic diversity and global spread of SARS-CoV-2,’ Nature

Dec. 8: ‘Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2,’ Science Advances

Dec. 8: ‘TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection,’ Science Advances

Dec. 7: ‘Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection,’ Nature

Dec. 6: ‘Interfering viral-like particles inhibit SARS-CoV-2 replication,’ Nature

Dec. 6: ‘Bamlanivimab and etesevimab monoclonal antibodies,’ Precision Vaccinations

Dec. 2: ‘4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication,’ Science

Dec. 2: ‘Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants,’ Science

Dec. 2: ‘Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain,’ Science

Dec. 2: ‘Hamster models of COVID-19 pneumonia reviewed: How human can they be?’ Veterinary Pathology

Dec. 1: ‘Will Africans take COVID-19 vaccination?’ PLOS One

Dec. 1: ‘Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta),’ Science Advances

NOVEMBER

BREAKING NEWS: Nov. 30: ‘Study compares NAbs from natural SARS-CoV-2 infection vs. vaccine induced against symptomatic infection,’ News Medical

Nov. 29: ‘Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern,’ News Medical

Nov. 25: ‘Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation,’ Nature

Nov. 24: ‘The N501Y spike substitution enhances SARS-CoV-2 infection and transmission,’ Nature

Nov. 23: ‘A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity,’ Nature

Nov. 23: ‘Modeling SARS-CoV-2 propagation using rat coronavirus-associated shedding and transmission,’ PLOS One

Nov. 23: ‘Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial,’ Science

Nov. 22: ‘Core genes involved in the regulation of acute lung injury and their association with COVID-19 and tumor progression: A bioinformatics and experimental study,’ PLOS One

Nov. 21: ‘Cross-reactive antibodies to SARS-CoV-2 and MERS-CoV in pre-COVID-19 blood samples from Sierra Leoneans,’ Viruses

Nov. 18: ‘Effective prophylaxis of COVID-19 in rhesus macaques using a combination of two parenterally-administered SARS-CoV-2 neutralizing antibodies,’ Frontiers in Cellular and Infection Microbiology

Nov. 18: ‘Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine,’ Nature

BREAKING NEWS: Nov. 16: ‘Animal models for SARS-CoV-2 infection and pathology,’ MedComm

Nov. 16: ‘An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice,’ Science Translational Medicine

Nov. 12: ‘SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains,’ Nature Communications

Nov. 9: ‘The role of T follicular helper cells in the humoral immune response to SARS-CoV-2,’ News Medical

Nov. 9: ‘An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination,’ Proceedings of the National Academy of Sciences of the United States of America

Nov. 9: ‘Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants,’ Science

Nov. 7: ‘Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model,’ EBioMedicine

Nov. 2: ‘Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2,’ Nature Medicine

Nov. 2: ‘An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19,’ Science

OCTOBER

Oct. 29: ‘Direct SARS-CoV-2 infection of the human inner ear may underlie COVID-19-associated audiovestibular dysfunction,’ Communications Medicine

Oct. 26: ‘Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms,’ Cell Research

Oct. 26: ‘Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques,’ News Medical

Oct. 26: ‘COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions,’ Proceedings of the National Academy of Sciences of the United States of America

Oct. 26: ‘Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission,’ Science Immunology

BREAKING NEWS: Oct. 25: ‘Clues that natural killer cells help to control COVID,’ Nature

Oct. 24: ‘Prediction of pandemic risk for animal-origin coronavirus using a deep learning method,’ Infectious Diseases of Poverty

Oct. 22: ‘Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques,’ Science Advances

Oct. 21: ‘Structure-guided antibody cocktail for prevention and treatment of COVID-19,’ PLOS Pathogens

Oct. 21: ‘Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine–boosted nonhuman primates,’ Science

Oct. 20: ‘COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models,’ Nature Communications

Oct. 20: ‘Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants,’ Science Advances

Oct. 20: ‘Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening,’ Scientific Reports

Oct. 18: ‘A pathogen-like antigen based vaccine confers immune protection against SARSCoV-2 in non-human primates,’ Cell Reports Medicine

Oct. 15: ‘Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dose, infection, and disease outcomes for coronavirus disease 2019 (COVID-19): A review,’ Clinical Infectious Diseases

Oct. 14: ‘Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK,’ Nature Medicine

Oct. 14: ‘Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model,’ PLOS Pathogens

Oct. 14: ‘mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern,’ Science

Oct. 14: ‘Replication and single-cycle delivery of SARS-CoV-2 replicons,’ Science

Oct. 12: Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses,’ Proceedings of the National Academy of Sciences of the United States of America

Oct. 8: ‘Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses,’ Journal of Experimental Medicine

Oct. 6: ‘Similarities and differences in the acute-phase response to SARS-CoV-2 in rhesus macaques and African green monkeys,’ Frontiers in Immunology

Oct. 5: ‘An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models,’ Science Translational Medicine

SEPTEMBER

Sept. 30: ‘Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors,’ Nature Medicine

Sept. 29: ‘A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques,’ bioRxiv

Sept. 29: ‘Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection,’ Nature Medicine

Sept. 28: ‘Exosome-mediated mRNA Delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity,’ Journal of Biological Chemistry

Sept. 23: ‘Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study,’ Science

Sept. 22: ‘Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques,’ PLOS Pathogens

Sept. 22: ‘Model Medicines announces preclinical data in study of orally available lead therapeutic (MDL-001) against COVID-19, in partnership with Scripps Research and Mount Sinai, demonstrating efficacy against primary endpoint,’ PR Newswire

Sept. 21: ‘Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy,’ Nature

Sept. 21: ‘Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients,’ News Medical

Sept. 21: ‘Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques,’ Proceedings of the National Academy of Sciences of the United States of America

Sept. 21: ‘Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice,’ Proceedings of the National Academy of Sciences of the United States of America

BREAKING NEWS: Sept. 21: ‘Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants,’ Science Translational Medicine

Sept. 13: ‘Virus-induced senescence is a driver and therapeutic target in COVID-19,’ Nature

Sept. 10: ‘Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro,’ Scientific Reports

Sept. 9: ‘Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial,’ Nature Medicine

Sept. 9: ‘The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology,’ Nature Medicine

Sept. 8: ‘Platelets amplify endotheliopathy in COVID-19,’ Science Advances

Sept. 7: ‘How many animals are used for SARS-CoV-2 research?’ EMBO Reports

Sept. 7: ‘Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection,’ PLOS Pathogens

Sept. 6: ‘SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion,’ Nature

Sept. 3: ‘Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial,’ Nature Medicine

Sept. 1: ‘Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques,’ Nature

AUGUST

Aug. 31: ‘Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies,’ Nature

Aug. 31: ‘Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination,’ Science

Aug. 31: ‘Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19,’ The Journal of Clinical Investigation

Aug. 30: ‘Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors,’ Nature Biotechnology

Aug. 27: ‘Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infection,’ The Journal of Clinical Investigation

Aug. 24: ‘Inhibition of elastase enhances the adjuvanticity of alum and promotes anti–SARS-CoV-2 systemic and mucosal immunity,’ Proceedings of the National Academy of Sciences

Aug. 23: ‘The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues,’ Viruses journal

Aug. 23: ‘Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19’

Aug. 20: ‘AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19,’ www.AstraZeneca.com

Aug. 18: ‘Pan-Sarbecovirus Neutralizing Antibodies in BNT 162b2-Immunized SARS-CoV-1 Survivors,’ New England Journal of Medicine

Aug. 17: ‘The Animal Origin of SARS-CoV-2,’ Science

Aug. 17: ‘A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants,’ Nature

Aug. 11: ‘Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients,’ New England Journal of Medicine

Aug. 11: ‘Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration,’ Communications Biology

Aug. 11: ‘Understanding lung damage in patients with COVID-19,’ Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Aug. 11: ‘Cell therapy strategies for COVID-19: Current approaches and potential applications,’ Science Advances

Aug. 10: ‘Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection and change to single dose vaccination,’ Journal of Medical Virology

Aug. 9: ‘Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model,’ PLOS Pathogens

Aug. 7: ‘Comparative sequence analysis of the accessory and nucleocapsid genes of feline coronavirus strains isolated from cats diagnosed with effusive feline infectious peritonitis,’ Archives of Virology

Aug. 5: ‘Clinical and histopathologic features of a feline SARS-CoV-2 infection model are analogous to acute COVID-19 in humans,’ Viruses

Aug. 4: ‘Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice,’ Scientific Reports

JULY

July 29: ‘Virus-like particles containing spikes induce strong sterile immunity to macaque SARS-CoV-2,’ ExBulletin

BREAKING NEWS: July 29: ‘Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates,’ Science

July 29: ‘Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers,’ Science Immunology

July 28: ‘How the coronavirus infects cells — and why Delta is so dangerous,’ Nature

July 28: ‘Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques,’ News Medical

July 26: ‘Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination,’ Nature Medicine

July 21: ‘Pre-clinical immune response and safety evaluation of the protein subunit vaccine Nanocovax for COVID-19,’ bioRxiv

July 21: ‘SAR1B senses leucine levels to regulate mTORC1 signalling,’ Nature

July 20: ‘Human tissue xenografts in murine models for the study of SARS-CoV-2,’ News Medical

July 20: ‘Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection,’ Proceedings of the National Academy of Sciences of the United States of America

July 20: ‘Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy,’ Proceedings of the National Academy of Sciences of the United States of America

July 20: ‘Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2,’ Science

July 19: ‘Broad sarbecovirus neutralization by a human monoclonal antibody,’ Nature

July 19: ‘Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques,’ PLOS Pathogens

July 15: ‘Intranasal gene therapy to prevent infection by SARS-CoV-2 variants,’ PLOS Pathogens

July 15: ‘SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney,’ PLOS Pathogens

BREAKING NEWS: July 15: ‘SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques,’ Science Immunology

July 14: ‘SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape,’ Nature

July 14: ‘Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination,’ Nature Medicine

July 13: ‘COVID-19 long haulers,’ Nature Biotechnology

July 12: ‘Systems vaccinology of the BNT162b2 mRNA vaccine in humans,’ Nature

July 9: ‘Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses,’ PLOS One

July 8: ‘A correlate of protection for SARS-CoV-2 vaccines is urgently needed,’ Nature Medicine

July 7: ‘Post COVID-19: A solution scan of options for preventing future zoonotic epidemics,’ Biological Reviews

July 6: ‘Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques,’ PLOS Pathogens

July 6: ‘Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy,’ PLOS Pathogens

July 1: ‘Can immune responses alone reveal which COVID-19 vaccines work best?’ Science

July 1: ‘Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants,’ Science

JUNE

June 30: ‘Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2,’ Nature

June 30: ‘Engineered single-domain antibodies tackle COVID variants,’ Nature

BREAKING NEWS: June 29: ‘Study suggests mRNA vaccines induce long-lasting COVID immunity,’ WDIV ClickOnDetroit

June 28: ‘SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,’ Nature

June 24: ‘Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis,’ JAMA Network Open

June 24: ‘Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicityClaim that Chinese team hid early SARS-CoV-2 sequences to stymie origin hunt sparks furor,’ Science

June 23: ‘Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques,’ Nature

June 23: ‘The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody,’ PLOS One

June 22: ‘Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2,’ Science

June 21: ‘Dysregulation of brain and choroid plexus cell types in severe COVID-19,’ Nature

BREAKING NEWS: June 21: ‘In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains,’ Nature

June 18: ‘No evidence of SARS-CoV-2 infection in Neotropical Primates sampled during COVID-19 pandemic in Minas Gerais and Rio Grande do Sul, Brazil,’ bioRxiv

June 18: ‘CureVac COVID vaccine let-down spotlights mRNA design challenges,’ Nature

June 10: ‘BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants,’ Nature

June 9: ‘Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans,’ Nature

June 8: ‘Senolytics reduce coronavirus-related mortality in old mice,’ Science

June 3: ‘Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants,’ Nature

June 1: ‘Cellular and humoral immune responses in mice immunized with vaccinia virus expressing the SARS-CoV-2 spike protein,’ The Journal of Immunology

June 1: ‘Conserved and novel mouse CD8 T cell epitopes within SARS-CoV-2 spike receptor binding domain protein identified following subunit vaccination,’ The Journal of Immunology

June 1: ‘Identification of T cell epitopes in the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 in rhesus macaques,’ The Journal of Immunology

MAY

May 28: ‘Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates,’ Science Advances

May 27: ‘BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans,’ Nature

May 25: ‘COVID-19 research: Lessons from non-human primate models,’ Vaccines

May 24: ‘Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 infection in nonhuman primates,’ bioRxiv

May 20: ‘CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer,’ Nature Medicine

May 20: ‘Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants,’ Science

May 19: ‘Diverse functional autoantibodies in patients with COVID-19,’ Nature

May 18: ‘Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19,’ Nature Medicine

May 18: ‘Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2,’ Science

BREAKING NEWS: May 17: ‘Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection,’ Nature Medicine

May 12: ‘Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein,’ PLOS One

May 12: ‘SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis,’ Nature

May 10: ‘Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses,’ Nature

May 5: ‘Delayed production of neutralizing antibodies correlates with fatal COVID-19,’ Nature Medicine

May 4: ‘Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes,’ Science

APRIL

April 29: ‘A molecular single-cell lung atlas of lethal COVID-19,’ Nature

April 29: ‘COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets,’ Nature

April 28: ‘Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP,’ Journal of Experimental Medicine

April 23: ‘Non-human primate models of human respiratory infections,’ Molecular Immunology 

April 22: ‘Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study,’ Nature Medicine

April 21: ‘Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2,’ News Medical

April 21: ‘Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization,’ PLOS Pathogens

April 19: ‘Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models,’ npj Vaccines

April 19: ‘Adjuvanting a subunit COVID-19 vaccine to induce protective immunity,’ Nature

April 15: ‘Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination,’ Science Immunology

April 12: ‘Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV,’ Nature

April 9: ‘Correlates of protection from SARS-CoV-2 infection,’ The Lancet

April 1: ‘Variation in predicted COVID‐19 risk among lemurs and lorises,’ American Journal of Primatology

MARCH

March 29: ‘Corona: New inhibitor identified – molecule blocks infection of cells with SARS-CoV-2 – but different from common antibodies,’ Archyde

March 26: ‘Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies,’ Nature Medicine

March 26: ‘SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model,’ Science

March 25: ‘Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England,’ Nature

March 25: ‘Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice,’ Nature

March 25: ‘SARS-CoV-2 infection of the oral cavity and saliva,’ Nature Medicine

March 25: ‘Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model,’ PLOS Pathogens

March 25: ‘Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy,’ Science

BREAKING NEWS: March 25: ‘mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection,’ Science

March 19: ‘Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans,’ Science Advances

BREAKING NEWS: March 19: ‘Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates,’ Science Advances

March 18: ‘Novel approaches for vaccine development,’ Cell

March 17: ‘SARS-CoV-2 viral dynamics in non-human primates,’ PLOS Computational Biology

March 16: ‘Clofazimine broadly inhibits coronaviruses including SARS-CoV-2,’ Nature

March 16: ‘Structural impact on SARS-CoV-2 spike protein by D614G substitution,’ Science

March 11: ‘Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies,’ Nature

March 11: ‘Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates,’ Scientific Reports

March 9: ‘“Does anyone have any of these?”: Lab-supply shortages strike amid global pandemic,’ Nature

March 9: ‘Pregnancy and COVID: what the data say,’ Nature

March 8: ‘Novel bioinformatics tool could help improve COVID-19 diagnosis,’ News Medical

March 5: ‘Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome,’ JAMA Neurology

March 4: ‘Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies,’ Nature Medicine

March 2: ‘Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics,’ Nature Medicine

March 1: ‘Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees,’ bioRxiv

March 1: ‘Identifying primate ACE2 variants that confer resistance to SARS-CoV-2,’ Molecular Biology and Evolution

FEBRUARY

Feb. 26: ‘SARS-CoV-2 spike D614G change enhances replication and transmission,’ Nature

Feb. 26: ‘Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A,’ Science

Feb. 24: ‘Comparative analysis of ACE2 protein expression in rodent, non-human primate, and human respiratory tract at baseline and after injury: A conundrum for COVID-19 pathogenesis,’ PLOS One

Feb. 23: ‘Biological activity-based modeling identifies antiviral leads against SARS-CoV-2,’ Nature Biotechnology

BREAKING NEWS: Feb. 21: ‘SARS-CoV-2 DNA vaccine tested in animal model,’ News Medical

Feb. 19: ‘Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody,’ Science

Feb. 17: ‘Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets,’ Science

Feb. 9: ‘SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801,’ Nature

Feb. 9: ‘Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection,’ The Journal of Clinical Investigation

Feb. 8: ‘Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera,’ Nature Medicine

Feb. 5: ‘SARS-CoV-2 evolution during treatment of chronic infection,’ Nature

Feb. 3: ‘Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents,’ Nature Biotechnology

Feb. 3: ‘Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape,’ Science

BREAKING NEWS: Feb. 1: ‘Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2,’ Nature

JANUARY

Jan. 30: ‘Impact of prior infection on protection and transmission of SARS-CoV-2 in golden hamsters,’ bioRxiv

Jan. 29: ‘Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera,’ Science

Jan. 25: ‘Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis,’ Nature

Jan. 25: ‘Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody,’ Science

Jan. 25: ‘Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A,’ Science

Jan. 22: ‘Rhesus macaques develop promising immune response to SARS-CoV-2,’ UC Davis

Jan. 21: ‘Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19,’ Molecular Therapy — Nucleic Acids

BREAKING NEWS: Jan. 21: ‘Monoclonal antibodies to disrupt progression of early COVID-19 infection,’ The New England Journal of Medicine

Jan. 20: ‘Lessons from the host defences of bats, a unique viral reservoir,’ Nature

Jan. 19: ‘Study identifies a nonhuman primate model that mimics severe COVID-19 similar to humans,’ Elsevier

Jan. 18: ‘Evolution of antibody immunity to SARS-CoV-2,’ Nature

Jan. 18: ‘Angiopoietin-2 is a crucial determinant of COVID-19 prognosis, study finds,’ News Medical

Jan. 14: ‘N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2,’ bioRxiv

Jan. 13: ‘Interim results of a phase 1–2a trial of Ad26.COV2.S COVID-19 vaccine,’ The New England Journal of Medicine

Jan. 12: ‘Immunological characteristics govern the transition of COVID-19 to endemicity,’ Science

Jan. 12: ‘Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice,’ Science

Jan. 12: ‘Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape,’ Science

Jan. 11: ‘Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques,’ bioRxiv

Jan. 8: ‘Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing,’ bioRxiv

Jan. 6: ‘Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,’ Science

Jan. 4: ‘Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques,’ bioRxiv

2020
DECEMBER

BREAKING NEWS: Dec. 30: ‘Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine,’ The New England Journal of Medicine

Dec. 24: ‘Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19,’ Nature Biotechnology

Dec. 24: ‘Cell-type apoptosis in lung during SARS-CoV-2 infection,’ www.biorxiv.org

Dec. 24: ‘Animal study suggests Palmitoylation Inhibitor reduces virulence of SARS-CoV-2,’ www.news-medical.net

Dec. 23: ‘Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus,’ PLOS Biology journal

Dec. 18: ‘Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets,’ Nature

Dec. 17: ‘Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses,’ Nature Medicine

Dec. 17: ‘T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial,’ Nature Medicine

Dec. 17: ‘Occurrence of antibodies against SARS-CoV-2 in the domestic cat population of Germany,’ Vaccines

Dec. 15: ‘COVID-19 is 10 times deadlier for people with Down syndrome, raising calls for early vaccination,’ Science

Dec. 14: ‘The coronavirus at 1: A year into the pandemic, what scientists know about how it spreads, infects, and sickens,’ STAT News

Dec. 10: ‘Targeted phage display-based pulmonary vaccination in mice and non-human primates,’ Med

Dec. 9: ‘Scientists show how SARS-CoV-2 causes multiple organ failure in experimental mouse model,’ ScienceAlert

Dec. 8: ‘The gastrointestinal tract is an alternative route for SARS-CoV-2 infection in a nonhuman primate model,’ Gastroenterology

Dec. 8: ‘Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK,’ The Lancet

Dec. 7: ‘Scientists discover how COVID-19 virus causes multiple organ failure in mice,’ UCLA

Dec. 5: ‘CAN HUMIDIFIERS ASSIST STOP COVID?’ Editorials 360

Dec. 4: ‘Researchers hunt for clues in our blood to discover COVID-19 vaccines of the future,’ ABC News

Dec. 1: ‘People with asthma are 30 percent LESS likely to contract COVID-19 – and it may be because their inhalers are helping to control the virus, study claims,’ Daily Mail

NOVEMBER

Nov. 30: ‘A novel SARS-CoV-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an adeno associated virus human angiotensin-converting enzyme 2 (AAV hACE2) mouse model,’ bioRxiv

Nov. 30: ‘Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in non-human primate and mice,’ bioRxiv

Nov. 30: ‘Toward superhuman SARS-CoV-2 immunity?’ Nature Medicine

Nov. 18: ‘Fever, aches from Pfizer, Moderna jabs aren’t dangerous but may be intense for some,’ Science

Nov. 18: ‘Why does COVID-19 seem to spare children? Vanderbilt University Medical Center study offers an answer,’ VUMC Reporter

Nov. 16: ‘Primate model used to explore features of SARS-CoV-2 infection,’ Drug Target Review

Nov. 15: ‘Identification of the SARS-CoV-2 virus features causing COVID-19 using primate model,’ National Research Council of Science and Technology

Nov. 15: ‘Researchers identify more features of virus causing COVID-19 using primate model,’ The Hindu Business Line

Nov. 13: ‘COVID mink analysis shows mutations are not dangerous — yet,’ Nature

Nov. 13: ‘SARS-CoV-2 exits cells via lysosomes,’ The Scientist

Nov. 12: ‘The immunology of multisystem inflammatory syndrome in children with COVID-19,’ Cell

Nov. 12: ‘Rhesus monkeys and cats potential spillover reservoirs for COVID-19 virus,’ News Medical

Nov. 12: ‘Mimicking SARS-CoV-2 nasal infection in monkeys,’ PLOS

Nov. 12: ‘SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo,’ Science

Nov. 12: ‘Common SARS-CoV-2 mutation may make coronavirus more susceptible to a vaccine,’ University of North Carolina at Chapel Hill

Nov. 10: ‘Researchers model how novel coronavirus causes severe symptoms of COVID-19,’ Beth Israel Deaconess Medical Center

Nov. 9: ‘Got a-fib? It could heighten COVID risks,’ HealthDay News

Nov. 5: ‘Comparison of SARS-CoV-2 infection in two non-human primate species: Rhesus and cynomolgus macaques,’ bioRxiv

Nov. 5: ‘De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2,’ Science

Nov. 3: ‘USP: Group investigates whether fat cells cause inflammation that aggravate COVID-19,’ Agência FAPESP

Nov. 3: ‘Cornea appears to resist infection from novel coronavirus,’ Washington University School of Medicine in St. Louis

Nov. 2: ‘Interferon deficiency can lead to severe COVID,’ Nature

OCTOBER

Oct. 30: ‘Colby Cosh: The hunt for the critter to blame for COVID,’ National Post

Oct. 29: ‘Dozens of introduction events sparked SARS-CoV-2 spread in Oregon, sequence data suggests,’ GenomeWeb

Oct. 29: ‘Corona: How antibodies can damage the brain and nerves,’ Newsy Today

Oct. 28: ‘Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants,’ eLife

Oct. 28: ‘NIH scientists discover key pathway in lysosomes that coronaviruses use to exit cells,’ National Institutes of Health

Oct. 28: ‘Identification of SARS-CoV-2 inhibitors using lung and colonic organoids,’ Nature

Oct. 28: ‘Robust neutralizing antibodies to SARS-CoV-2 infection persist for months,’ Science

Oct. 27: ‘WSU COVID-19 research tackles the present and future pandemic,’ WSU News

Oct. 26: ‘Taconic Biosciences launches critical model for COVID-19 research,’ Globe Newswire

Oct. 26: ‘Spike mutation D614G alters SARS-CoV-2 fitness,’ Nature

Oct. 22: ‘What we know so far about how COVID affects the nervous system,’ Scientific American

Oct. 21: ‘Cats with COVID-19 naturally develop antibodies to fight virus,’ PuppyConnection

Oct. 20: ‘Research team describes how a virus can cause diabetes,’ Spanish National Cancer Research Center

Oct. 20: ‘Neuropilin-1 drives SARS-CoV-2 infectivity, finds breakthrough study,’ University of Bristol

Oct. 14: ‘Will SARS-CoV-2 become endemic?’ Science

Oct. 14: ‘Coronavirus vaccine: What we know so far – a comprehensive guide by academic experts,’ The Conversation

Oct. 12: ‘SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies,’ Nature

Oct. 8: ‘Reduced severe acute respiratory syndrome coronavirus 2 entry factors and enhanced innate immune gene expression in the nasal epithelium of pregnant rats,’ American Journal of Obstetrics and Gynecology

Oct. 8: ‘Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection,’ Nature

Oct. 6: ‘Arizona study: Coronavirus infection relieves pain in rodents,’ KNAU

Oct. 6: ‘Older heavier COVID-19 positives likely to be superspreaders,’ News Medical

Oct. 5: ‘RNA analysis at heart of COVID-19 testing,’ Cornell Chronicle

Oct. 5: ‘Mist begins to clear for lung delivery of RNA,’ Nature Biotechnology

Oct. 2: ‘Strong evidence of zoonotic COVID-19 transmission: Study shows SARS-CoV-2 jumped between people and mink,’ European Society of Clinical Microbiology and Infectious Diseases

SEPTEMBER

Sept. 30: ‘This biologist helped trace SARS to bats. Now, he’s working to uncover the origins of COVID-19,’ Science

Sept. 29: ‘Studies begin to untangle obesity’s role in COVID-19,’ The New York Times

Sept. 28: ‘Coronavirus could invade the brain, two Yale studies suggest,’ Yale Daily News

Sept. 23: ‘Cats with COVID-19 naturally develop antibodies to fight virus, tests show,’ CTV News

Sept. 23: ‘Animal models for COVID-19,’ Nature

Sept. 21: ‘Why COVID-19 patients are suffering from distorted and phantom smells,’ Smithsonian Magazine

Sept. 18: ‘Pigs do not transmit COVID-19, according to K-State study,’ Pork Magazine

Sept. 17: ‘How did coronavirus get transferred from animals to humans? Scientists may have an answer,’ ABC News

Sept. 17: ‘Study shows SARS-CoV-2 jumped between people and mink, providing strong evidence of zoonotic transmission,’ European Society of Clinical Microbiology and Infectious Diseases

Sept. 17: ‘Pitt scientists isolate tiny molecule that may prevent COVID-19,’ PhillyVoice

Sept. 15: ‘Animal testing discovers new antibody component for fight against COVID,’ National Review

Sept. 15: ‘How COVID-19 can damage the brain,’ Nature

Sept. 14: ‘Susceptibility of domestic pigs to SARS-CoV-2,’ News Medical

BREAKING NEWS: Sept. 14: ‘Pitt scientists discover tiny antibody component that is highly effective in preventing and treating SARS-CoV-2 infection in animal models,’ University of Pittsburgh

Researchers reported promising results with mice and hamsters.

“Ab8 not only has potential as therapy for COVID-19, but it also could be used to keep people from getting SARS-CoV-2 infections,” said John Mellors, chief of the Division of Infectious Diseases at Pitt and UPMC.

Sept. 12: ‘Pigs can be infected with coronavirus, Canadian-US study finds,’ South China Morning Post

Sept. 11: ‘The hunt for a corona vaccine: This is how vaccine research goes,’ Corona 24 News

Sept. 9: ‘The coding capacity of SARS-CoV-2,’ Nature

Sept. 9: ‘How the coronavirus attacks the brain,’ The New York Times

Sept. 8: ‘What bats can teach us about developing immunity to COVID-19,’ Financial Times

Sept. 3: ‘As COVID-19 continues, experts warn of next pandemic likely to come from animals,’ ABC News

Sept. 3: ‘What are interferons: The “front-line soldiers” with whom our body fights the coronavirus (and what dangers they have),’ Newsdotes.com

Sept. 3: ‘A common North American mouse can catch and spread the coronavirus in labs, studies show,’ The Washington Post

Sept. 2: ‘In animal research, nanoparticle therapy induces antibodies towards SARS-CoV-2,’ Home Health Choices

Sept. 2: ‘In animal studies, nanoparticle treatment induces antibodies against SARS-CoV-2,’ Medical Xpress

Sept. 2: ‘Study shows SARS-CoV-2 jumps back and forth between animals and humans on mink farms,’ News-Medical.net

Sept. 1: ‘Jumping back and forth: anthropozoonotic and zoonotic transmission of SARS-CoV-2 on mink farms,’ bioRxiv

AUGUST

Aug. 31: ‘Mouse-adapted SARS-CoV-2 model provides new tool for COVID-19 discoveries,’ University of North Carolina

Aug. 31: ‘Do vultures and condors spread diseases?’ Forbes.com

Aug. 28: ‘Transgenic mice will accelerate COVID-19 vaccine and drug studies,’ Corona 24 News

Aug. 27: ‘Amazon and Congo Basin focus of new emerging infectious disease research center,’ UC Davis

Aug. 27: ‘A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures,’ Nature

Aug. 26: ‘Flu virus can travel on dust particles. Does the same hold true for coronavirus?’ HealthDay News

Aug. 26: ‘Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020,’ PLOS Pathogens

Aug. 25: ‘Analysis: Endangered species at risk from COVID-19, study says,’ Connecticut Post 

Aug. 24: ‘UCLA studies COVID-19’s potential spread from animals to humans,’ The Antelope Valley Times

Aug. 23: ‘Many animal species may be vulnerable to coronavirus infection, study says,’ News18

Aug. 23: ‘Which animals can become infected by the coronavirus?’ Victoria Advocate

Aug. 21: ‘Genomic analysis reveals many animal species may be vulnerable to SARS-CoV-2 infection,’ UC Davis

Aug. 19: Comparison of nonhuman primates identified the suitable model for COVID-19,’ Signal Transduction and Targeted Therapy

Aug. 18: ‘Dust can spread influenza among guinea pigs, raising coronavirus questions,’ Science News

Aug. 17: ‘Structures and distributions of SARS-CoV-2 spike proteins on intact virions,’ Nature

Aug. 17: ‘What the immune response to the coronavirus says about the prospects for a vaccine,’ Nature

Aug. 12: ‘Might SARS‐CoV‐2 have arisen via serial passage through an animal host or cell culture?’ BioEssays

Aug. 10: ‘Can designer mice save us from COVID-19?’ The New Yorker

Aug. 6: ‘Scientists may be using the wrong cells to study COVID-19,’ WIRED

Aug. 5: ‘New model may help in successfully translating data from animal studies to humans,’ Genetic Engineering & Biotechnology News

Aug. 1: ‘Early insights into immune responses during COVID-19,’ The Journal of Immunology

JULY

July 31: ‘Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia,’ Science Advances

July 30 : ‘Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy,’ Science

July 29: ‘COVID-19: Infectious coronaviruses “circulating in bats for decades,”’ BBC News

July 29: ‘Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis,’ Nature

July 29: ‘A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity,’ Nature

July 29: ‘Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity,’ Nature

July 28: ‘New coronavirus turns out to be decades old — in bats,’ Bloomberg

July 28: ‘Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic,’ Nature Microbiology

July 23: ‘LSU SVM Center for Lung Biology and Disease investigates lung and lung-related heart diseases during the COVID-19 pandemic,’ LSU School of Veterinary Medicine

July 23: ‘A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction,’ Nature Biotechnology

July 23: ‘Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody,’ Science

July 23: ‘Scientists at Texas Biomed establish a human transgenic mouse model susceptible to SARS-CoV-2 infection,’ Texas Biomedical Research Institute

July 22: ‘Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike,’ Nature

July 22: ‘Six reference-quality genomes reveal evolution of bat adaptations,’ Nature

July 22: ‘How bats have outsmarted viruses—including coronaviruses—for 65 million years,’ Science

July 21: ‘Distinct conformational states of SARS-CoV-2 spike protein,’ Science

July 17: ‘SARS-CoV-2 failure to infect or replicate in mosquitoes: An extreme challenge,’ Nature

July 16: ‘Coronavirus may have come from bats; could they also hold clues to treatments?’ HealthDay News

July 15: ‘SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls,’ Nature

July 14: ‘Red blood cells harnessed as nanoparticle carriers for vaccines,’ Genetic Engineering & Biotechnology News

BREAKING NEWS: July 14: ‘Study in primates finds acquired immunity prevents COVID-19 reinfections,’ NIH Director’s Blog

“While more study is needed to understand details of the immune responses, researchers did detect a reassuring appearance of antibodies specific to the SARS-CoV-2 spike protein in the macaques over the course of the first infection. The spike protein is what the virus uses to attach to macaque and human cells before infecting them,” Dr. Francis Collins wrote.

July 13: ‘Coronavirus: Llamas provide key to immune therapy,’ BBC News

July 13: ‘Bat research could help prevent the next coronavirus, WSU professor says,’ KREM 2 News

July 13: ‘University signs research agreement for COVID-19 vaccine candidate,’ K-State News

July 13: ‘A perspective on potential antibody-dependent enhancement of SARS-CoV-2,’ Nature

July 13: ‘Here’s how scientists know the coronavirus came from bats and wasn’t made in a lab,’ The Conversation

July 13: ‘Bat research critical to preventing next pandemic,’ WSU News

July 8: ‘Putting hamsters on an a plane could prove whether the coronavirus can be spread through airborne transmission, infectious disease expert says,’ Daily Mail

July 8: ‘A COVID-19 model,’ Nature Biotechnology

“A mouse model of COVID-19 that mirrors several features of human disease has been developed using CRISPR–Cas9 knock-in technology. The model is the first to contain only the human version of the angiotensin-converting enzyme 2 (ACE2) — the receptor SARS-CoV-2 uses to enter cells,” the article said.

July 8: ‘Animal studies could help test for COVID-19 airborne transmission,’ PA Media

July 8: ‘Bats and COVID,’ University of Pennsylvania School of Veterinary Medicine

July 7: ‘Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques,’ Cell Research

July 7: ‘Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),’ Experimental Biology and Medicine

July 6: ‘Macaques develop short-term immunity to SARS-CoV-2,’ Drug Target Review

July 6: ‘Tulane researchers find that coronavirus can survive in air for hours,’ Tulane

“We saw very little deterioration in the infectiousness of these aerosols after 16 hours,” said Chad Roy, lead investigator and director of infectious disease aerobiology at the Tulane National Primate Research Center. “This is notable because we would expect it to behave similar to other coronaviruses that begin to decay over this amount of time – and, it didn’t.”

July 5: ‘Mice hold key in COVID vaccine rat race,’ The Times of India

July 4: ‘Coronavirus: Infected monkeys were protected from reinfection a month later,’ South China Morning Post

July 2: ‘Monkeys infected with novel coronavirus developed short-term immunity,’ Agence France-Presse

July 2: ‘Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques,’ Science

July 2: ‘This coronavirus mutation has taken over the world. Scientists are trying to understand why,’ The Washington Post

“Scientists may be able to rule out these alternative explanations with more rigorous statistical analyses or a controlled experiment in an animal population,” WaPo reported.

JUNE

June 30: Studying SARS-CoV-2 spread in poultry and domestic animals,’ The Poultry Site

June 29: ‘Does PFAS exposure add to COVID-19 risk? Shaheen, senators push to find out,’ Seacoastonline.com

New Hampshire Democratic Sen. Jeanne “Shaheen and the other senators also noted that the Agency for Toxic Substances and Disease Registry (ATSDR) issued a ‘Statement on Potential Intersection between PFAS Exposure and COVID-19’ earlier this month,” the report said. “This statement indicated that ‘there is evidence from human and animal studies that PFAS exposure may reduce antibody responses to vaccines … and may reduce infectious disease resistance,’” Shaheen and other senators wrote.

June 28: ‘University of Iowa researchers develop mice model to study COVID-19 symptoms,’ The Daily Iowan

June 27: ‘Bats carry coronaviruses but don’t get sick. Could their secret help us fight COVID-19?’ The Philadelphia Inquirer

June 26: ‘Modeling harmony: Learning from preclinical coordination of COVID-19 countermeasures,’ BioCentury

“There was never a coordination to this level, where we would be using a master protocol and harmonizing as much as we can across centers with shared controls,” said Jay Rappaport, a leader of ACTIV’s nonhuman primate work.

June 24: ‘Mounting clues suggest the coronavirus might trigger diabetes,’ Nature

“The virus also attacked pancreatic organoids that had been transplanted into mice, and cells in liver organoids. … The organoid study[8] adds strength to the argument that SARS-CoV-2 might cause or worsen diabetes, but the paper itself is not enough to prove the link, says [scientist Abd] Tahrani,” the article said.

June 22: ‘Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development,’ Proceedings of the National Academy of Sciences of the United States of America

June 22: ‘Hamsters develop protective immunity to COVID-19 and are protected by convalescent sera,’ University of Wisconsin–Madison

June 19: ‘People probably caught coronavirus from minks. That’s a wake-up call to study infections in animals, researchers say,’ The Washington Post

June 18: ‘Measles origin finding could inform COVID-19 research,’ Medical Xpress

“Alongside the findings published in Science, Australian evolutionary experts from the University of Sydney and University of Melbourne have published a complementary Perspective, proposing that similarly refining research about when COVID-19 and other zoonotic diseases emerged will assist in understanding how such pathogens jump from animals to humans,” the article said.

June 18: ‘First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection,’ News Medical

“In order to identify host genes indispensable for cell survival in response to SARS-CoV-2, this group of researchers decided to use the African green monkey cell line Vero-E6, which is highly amenable to SARS-CoV-2 infection and virus-induced cytopathic effects,” the article said.

June 18: ‘Tonix and Southern Research to study immune responses to COVID-19,’ Pharmaceutical Technology

“The partners formed an alliance in March this year to develop a vaccine against Covid-19 using Tonix’s horsepox vaccine platform. They agreed to develop and conduct animal testing of TNX-1800, a live modified horsepox virus vaccine formulated for percutaneous administration,” the article noted.

June 17: ‘Off-the-shelf tool for making mouse models of COVID-19,’ University of Iowa Carver College of Medicine

June 16: ‘Immune status could determine efficacy of COVID-19 therapies,’ Nature

“In cells and animal models, SARS-CoV-2 induced abnormally low levels of transcripts downstream of type I and type III interferons, juxtaposed with high levels of cytokines such as IL-6, Benjamin tenever, of the Icahn School of Medicine at Mount Sinai, and his colleagues recently reported,” the article said.

June 15: ‘Scripps scientists: mutation makes coronavirus more infectious,’ CBS12

“Our data certainly implies that it will be more transmissible, but more animal experiments will be necessary,” Dr. Hyeryun Choe said.

June 12: ‘Genetically engineered lab mice to boost COVID-19 vaccine and research: Experts,’ International Business Times UK

June 12: ‘Researchers focus on COVID-19 virus in animals,’ Journal of the American Veterinary Medical Association

June 11: ‘Immunity to the coronavirus remains a mystery. Scientists are trying to crack the case,’ STAT News

“But with animals, researchers can ‘challenge’ those that are vaccinated or have had an initial infection to see if they can ward the virus off — which is what recent studies in monkeys demonstrated. Scientists found that the animals generated neutralizing antibodies after they first contracted the virus or when they were given experimental vaccines, and that the higher the level of the antibodies the monkeys had (the higher the ‘titer,’ in scientific parlance), the more protected they were against the pathogen when scientists sprayed a second dose into their noses,” STAT noted.

June 11: ‘Mouse model of COVID-19, key in accelerating research, developed by Washington U.,’ St. Louis Post-Dispatch

June 11: ‘An animal model of COVID-19 is now available,’ The Economist

June 10: ‘Mice can’t catch COVID-19, so a UA lab is making new kind of mouse,’ Arizona Republic

June 10: ‘A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies,’ Cell

June 10: ‘Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment,’ Cell

“It is critical that vaccines and therapeutics be developed very rapidly. Mice, the ideal animal for assessing such interventions, are resistant to SARS-CoV-2,” the article’s summary said. “Here, we overcome this difficulty by exogenous delivery of human ACE2 with a replication-deficient adenovirus (Ad5-hACE2).”

BREAKING NEWS: June 10: ‘New COVID-19 “mouse model” can speed the search for drugs and vaccines, researchers say,’ Fox News

“Mice are useful because you can study a large number of them and observe the course of the disease and the immune response in a way that is hard to do in people. It would be more cost-effective and efficient and safer for people if we could get more information about how these potential drugs and vaccines work and how effective they are before we move to more challenging non-human primate and ultimately human studies,” said principal investigator Michael S. Diamond.

June 10: ‘Potential COVID-19 vaccine from China shows promise in animal tests,’ Reuters

June 10: ‘COVID-19 mouse model will speed search for drugs, vaccines,’ Washington University School of Medicine

June 9: ‘COVID-19 produces lung inflammation in non-human primate experiments,’ News Medical

June 3: ‘Why coronavirus hits men harder: Sex hormones offer clues,’ Science

“Researchers haven’t established that androgens control TMPRSS2 in the lung—ground zero for SARS-CoV-2 infection—as they do in the prostate; studies in lung tissue and cells from mice and humans come to conflicting conclusions,” the article noted.

June 2: ‘Texas Biomed: Larger primates best model in COVID-19 vaccine study,’ Rivard Report

June 1: ‘Scientists find a way to infect mice with coronavirus. Here’s why that’s so important,’ ScienceAlert

MAY

May 29: ‘Pangolins may have incubated the novel coronavirus, gene study shows,’ CNN

May 29: ‘Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model,’ Science

May 28: ‘WSU is testing animals for COVID-19 to learn more about how the virus moves between species,’ The Pacific Northwest Inlander

May 28: ‘Data: Sunlight, heat kills coronavirus on surfaces,’ WWL-TV

These results come from the Tulane National Primate Research Center.

May 27: ‘New research points to bats as the origin of the novel coronavirus,’ BGR

May 27: ‘Mouse model mimics SARS-CoV-2 infection in humans,’ ScienceDaily

May 23: ‘Oregon research trial finds COVID-19 post-infection immunity in primates,’ The Corvallis Advocate

May 22: ‘Primate studies offer hope for future COVID-19 vaccine development,’ Infectious Disease Hub

May 22: ‘Oregon primate study gives hope for post-infection immunity to COVID-19,’ Oregon Public Broadcasting

May 21: ‘Monkeys in coronavirus tests “develop immunity” in two different studies,’ Daily Star

BREAKING NEWS: May 21: ‘Scientists made a mouse embryo that’s 4% human — the highest level of human cells in an animal yet,’ CNN

“Such chimeric mice would be very useful for studying COVID-19, which gravely impacts human, but barely affects mice,” State University of New York at Buffalo physiology and biophysics professor Jian Feng said.

May 20: ‘SARS-CoV-2 infection protects against rechallenge in rhesus macaques,’ Science

May 19: ‘Wearing a mask can significantly reduce coronavirus transmission, study on hamsters claims,’ CNBC

May 14: ‘Millions of human cells grow in mouse embryo in 17 days,’ Futurity

“Further development of our technology could enable the generation of even larger quantities of specific types of mature human cells to allow us to create more effective mouse models to study diseases that gravely affect humans, such as malaria or COVID-19,” said professor Jian Feng.

BREAKING NEWS: May 14: ‘Building a mouse squad against COVID-19,’ Knowable Magazine

“It began with an email from Wuhan, a Maine laboratory and mouse sperm from Iowa. Now that lab is on the verge of supplying a much-needed animal for SARS-CoV-2 research,” the outlet said.

May 14: ‘Infection of dogs with SARS-CoV-2,’ Nature

May 14: ‘Iowa mice key in race for COVID-19 treatments,’ The Des Moines Register

May 12: ‘Respiratory disease in rhesus macaques inoculated with SARS-CoV-2,’ Nature

May 11: ‘The search for a Covid-19 research animal model,’ WIRED

Also, check out FBR’s white paper “The Critical Role of Nonhuman Primates in Medical Research” (linked here).

May 8: ‘Pangolins hold clues to how COVID-19 began — and might end,’ HealthDay News

May 4: ‘Structure of COVID-19 virus hints at key to high infection rate,’ Cornell Chronicle

APRIL

April 30: ‘Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,’ bioRxiv

April 30: ‘Why you should avoid some cough syrups if you think you’ve got the coronavirus,’ Los Angeles Times

“In tests conducted at the Pasteur Institute in Paris, researchers found that when dextromethorphan was introduced into the cells of African green monkeys growing in petri dishes, the subsequent addition of SARS-CoV-2 resulted in more prolific viral growth,” the report said.

April 26: ‘Recombinant protein produces neutralizing COVID-19 antibodies in primate model,’ News Medical

April 24: ‘Vaping, opioid addiction accelerate coronavirus risks, says NIDA director,’ Kaiser Health News

“We know from animal experiments that vaping itself — not even giving any drugs with it — can produce inflammatory changes in the lung,” National Institute on Drug Abuse Director Nora Volkow told Kaiser Health News.

BREAKING NEWS: April 21: ‘COVID-19 infection model described in cynomolgus macaques,’ Genetic Engineering & Biotechnology News

Researchers in the Netherlands infected cynomolgus macaques with a clinical isolate of SARS-CoV-2.

“This study provides a novel infection model, which will be critical in the evaluation and licensure of preventive and therapeutic strategies against SARS-CoV-2 infection for use in humans,” they wrote.

BREAKING NEWS: April 18: ‘Is COVID-19 “reinfection” possible? What a study on monkeys shows,’ Gulf News

“People who have been vaccinated against chickenpox have been noted to contract it after many years, but in such cases, the symptoms are less severe. We may find a similar trend occurring with the novel coronavirus. As of now however, we simply do not have enough data,” said Dr. Rasha Alani.

April 17: ‘From mice to monkeys, animals studied for coronavirus answers,’ Science

April 13: ‘How monkeys, ferrets, and horses are helping scientists fight COVID-19,’ Quartz

April 13: ‘Mice, hamsters, ferrets, monkeys. Which lab animals can help defeat the new coronavirus?’ Science

April 10: ‘Single-cell atlas of a non-human primate reveals new pathogenic mechanisms of COVID-19,’ bioRxiv

MARCH

March 26: ‘Significance of pangolin viruses in human pandemic remains murky,’ The New York Times

March 18: ‘Macaque monkeys can’t become reinfected with COVID-19, small study suggests,’ Live Science

BREAKING NEWS: March 18: ‘Coronavirus origins: Genome analysis suggests two viruses may have combined,’ The Conversation

“In the space of a few weeks, we have all learned a lot about COVID-19 and the virus that causes it: SARS-CoV-2. But there have also been a lot of rumours,” the article said. “And while the number of scientific articles on this virus is increasing, there are still many grey areas as to its origins.”

March 17: ‘COVID-19 coronavirus epidemic has a natural origin,’ ScienceDaily

March 16: ‘Which species transmit COVID-19 to humans? We’re still not sure,’ The Scientist

BREAKING NEWS: March 14: ‘These lab animals will help fight coronavirus,’ The New York Times

Researchers, such as those at The Jackson Laboratory in Maine, are breeding transgenic mice. Experts will test different strains of transgenic mice as well as a variety of other laboratory animals including nonhuman primates to determine which ones are susceptible to infection with the virus.

March 5: ‘From ferrets to mice and marmosets, labs scramble to find right animals for coronavirus studies,’ STAT

“Every day, it seems another company announces an attempt to make its own virus-fighting vials. But to test an experimental formulation, scientists can’t just jump from Petri dishes into people,” STAT News reporter Eric Boodman wrote. “They need to try it in critters first, to check that the stuff is safe and effective.”

FEBRUARY

Feb. 17: ‘Live coronavirus samples now at Tulane’s Primate Center on Northshore for research,’ WWL-TV (New Orleans)The Tulane National Primate Research Center launched a research project to understand COVID-19 with animal models. The researchers are trying to understand how the disease spreads and progresses in nonhuman primates.

Keep checking this page and social media channels, as well as our weekly SmartBrief, for future updates on animal research in the fight against COVID-19.

Photo credit: Foundation for Biomedical Research

Photo credit: Samara Heisz / iStock / Getty Images Plus

Photo credit: 4X-image / Getty
Photo credit: unoL / iStock / Getty Images Plus
Photo credit: gorodenkoff / iStock / Getty Images Plus
Featured photo credit: BlackJack3D / Getty

What is Animal Research?

Animal research is the study of animals for scientific and medical discovery. Research animals, also called lab animals, are bred specifically for research. Studying lab animals gives researchers important insights into how a disease works in the body. Once they understand how a disease works, they can begin to develop and test treatments with the help of animals.  

What is Animal Testing?

Animal testing is essential for understanding the safety and proper dosages of new medicines and treatments. If researchers find that a drug is safe and effective through animal testing, they can begin testing it in small groups of people and then larger groups of people. Both extensive human and animal testing is required by law before a drug can be approved. 

Why is it necessary?

Nearly every medicine, medical device, surgical procedure or therapy we have today has depended on animal testing and research. It’s one of the first steps in medical discovery. To understand how a disease works in the body, scientists study the disease in animals. Animal research gives them the knowledge they need to discover and create treatments to help both people and animals living with illnesses.

Support Biomedical Research

For people, for animals, for the common good

%d bloggers like this: